Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022
Global Multi Infarct Dementia Market Research Report 2016 by OBRC, is an extensive study on present state of the Multi Infarct Dementia Market. The global multi-infarct dementia is estimated to reach $1,3400million at CAGR 12.7% during 2016-2022.
Multi infarct dementia is a common cause of memory loss among the elderly people between age group 55 to 75 years. Multi infarct dementia is triggered by multiple strokes to the brain it is also called as vascular dementia. According to National Institute of Health epidemiological study, multi infarct dementia accounts for over 20% dementia cases among people with age group above 65 years. Growing geriatric population in the world and rising number of brain strokes would escalate the incidence of multi infarct dementia. American Stoke Association, in its 2016 epidemiological report on stroke, projected the global prevalence rate of stroke accounted for one in five per 1000 person. In U.S. nearly 800,000 people have a stroke every year, according to American Stroke Association. By 2030 stroke prevalence will rise around 20% more than 2012 level. There are no practicable treatment options for multi infarct dementia, other than early diagnosis and routine therapy.
Early diagnosis involves assessing individual cognitive ability, medical history, brain scans like computed topography (CT) or magnetic resonance imaging (MRI) scans. Changing regulatory compliance rules of different countries pose a challenge for market growth in the region.
Aging countries like Japan, Italy, Greece and Germany are the major markets for multi-infarct dementia. North America has been the dominant market for multi infarct dementia in last two fiscal years (2015 & 2016) followed by Europe. Asia Pacific and Latin America is the fastest growing multi infarct dementia market for the forecasted period.
Increasing geriatric population, rising prevalence of strokes and increasing healthcare spending are the growth drivers discussed in multi-infarct dementia market research report. Emerging Economies and technological advancements in inhibitors are opportunities in deliberated in multi-infarct dementia market report for the forecasted period.
Varying regulatory environment of different countries and unavailability of treatment therapy are the restraining issues discussed in multi infarct dementia market report. Lack of awareness about dementia as a disease is a challenge for the market growth.
The research report is segmented in terms of pharmacological treatment and causes of dementia. The pharmacological treatment segment is further sub segmented into cholinesterase inhibitors, memantine, nimodipine, hydergine, and cytidine 5’-diphosphocholine (CDP-Choline), and other drug classes like selective serotonin reuptake inhibitors, calcium channel blockers, and angiotensin-converting-enzyme inhibitors. Cholinesterase inhibitors are further divided into donepezil, galantamine, and rivastigmine. Causes of dementia are further classified into anaemia, brain tumour, chronic infection, depression, thyroid disease, vitamin deficiency, and drug intoxication.
Some of the leading companies are Accelerys Inc., Affymetrix Ltd., Agilent Technologies., Celera Corporation., DNAexus Ltd., Forest Laboratories Inc., Geneva Bioinformatics., GVK Biosciences Ltd., IBM Life Science Ltd., Illumina Inc., Janssen Pharmaceuticals Inc., Life Technologies Corporation., Novartis Pharmaceutical Corporation., Pfizer Inc., and Siegen Inc. The report provides comprehensive information like company profile, sales, revenue, market share and contact information.
Joint ventures, agreements, partnerships, collaborations, expansion in different countries, and strengthening supply chain network with distributors are some of the strategies taken by pioneers in multi-infarct dementia market, to increase their global presence. Research & development investments are high with the urge to develop quality and environmental friendly products. Amarantus biosciences Inc., is currently undergoing its third phase clinical trials on drug Eltoprazine, after successful phase two trials on December 2015. Small pharmaceutical firms with unique and differentiated assets are driving innovation in multi-infarct dementia market.
The research report analysed multi-infarct dementia market geographically. Region wise the report is segmented as North America, Europe, Asia Pacific, and Rest of the World.
North America is the largest market for multi-infarct dementia market followed by Europe. Increasing cases of multi infarct dementia and growing geriatric population are the factors driving multi-infarct dementia market in the region. Multi-Infarct Dementia accounts for 30% of all dementia cases in North America and Europe.
Asia Pacific is the fastest growing multi-infarct dementia market for the forecasted period. Rising geriatric population, increased healthcare spending, and changing healthcare reforms are the factors driving multi-infarct dementia market in the region for the forecasted period. Multi-Infarct dementia accounts for over 50% of the dementia cases in Japan.
Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.